Notifications

- 2023.07.31Summit Pharmaceuticals International Corporation Statement for UK Modern Slavery Act 2015 (FY 2022 Statement)
- 2023.06.02Signing of Exclusive Distributorship Agreement with EVERZOM
- 2022.06.30Summit Pharmaceuticals International Corporation Statement for UK Modern Slavery Act 2015 (FY 2021 Statement)
- 2022.04.14Fukushima Medical University aim to accelerate cancer research by contributing their patient derived organoids to the CancerTools.org initiative
- 2021.10.05Sumitomo Corporation Group Statement for UK Modern Slavery Act 2015 (FY 2020 Statement)
- 2021.09.30CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan’s Top Pharmaceutical Companies
- 2020.10.19Sumitomo Corporation Group Statement for UK Modern Slavery Act 2015 (FY 2019 Statement)
- 2020.02.14Summit Pharmaceuticals International Corporation Invests in Luxna Biotech Co., Ltd. Possessing the Nucleic Acid Pharmaceutical Element Technologies
- 2019.10.25Signed a Contract for Sale of Stem Cells from Human Exfoliated Deciduous Teeth between Gene Techno Science Co., Ltd. and Summit Pharmaceuticals International Corporation.
- 2019.10.07Sumitomo Corporation Group Statement for UK Modern Slavery Act 2015 (FY 2018 Statement)
- 2019.10.01Establishment of a new cosmetics company
- 2019.03.14CytoReason and Summit Pharmaceuticals International Forge Commercial Alliance To Bring CytoReason’s Machine Learning Model of the Immune System for Drug Discovery & Development To Japanese Drug Makers